On Wednesday, at the 75th Annual Meeting of the College on Problems of Drug Dependence, Nektar Therapeutics (NASDAQ:NKTR) announced positive results for the human abuse liability study for NKTR-181 which is a very promising new drug candidate in Nektar's pipeline that is being developed as an analgesic for the treatment of chronic pain. According to Nektar's President and CEO Howard Robin, "The NKTR-181 molecule has been designed to enter the CNS slowly to reduce the dopamine rush and its associated euphoria that lead to the abuse of and addiction to current opioid analgesics." Read about the results here. In other words NKTR-181 is designed to be the first non-addictive opioid painkiller.
The problem of addiction and abuse...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|